8/8/2013

Japan's Health, Labor and Welfare Ministry is considering rules to penalize companies that fail to preserve and submit clinical trial data to the government. Possible penalties include fines, revocation of drug approvals and suspension of clinical trials.

Full Story:
PharmaLive.com

Related Summaries